SynthesisJournal of neurology2026
Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesParaneoplastic neurological syndromes (PNSs) are a group of neurological disorders linked to malignancies. Their clinical trajectory, differential diagnoses, immune-mediated mechanisms, and outcomes remain inadequately understood. The review aims to improve our understanding of the main syndrome and its clinical progression by systematic review of studies involving patients with anti-Ri-antibody-associated paraneoplastic neurological syndrome (Ri-PNS).
methodsThe protocol adhered to the PRISMA guidelines and is registered with PROSPERO (ID: CRD420251152531).
resultsEighty-five cases with comprehensive clinical data were identified, with a median age of 61.0 ± 11.8 years, and the majority were female (78.6%). At the disease onset, ataxia was the most prevalent neurological symptom (70.6%). Ataxia rarely manifested as a state of isolation, and was frequently accompanied by other symptoms: tremor, dysarthria, spasticity, and dystonia. Twenty-six patients (30.6%) developed opsoclonus, and 22.4% developed myoclonus. The median interval from the onset of PNS to cancer diagnosis was 1.5 months (IQR, 0-7.0 months). Breast cancer was frequently observed in female patients (65.2%), whereas lung cancer was more common in male patients (38.9%). Of the patients with cancer, fifty-eight received oncological treatment. In addition, 62/85 patients (72.9%) underwent immunotherapy.
conclusionsRi-PNS is a multisystem neurological syndrome with significant involvement of the cerebellum and brainstem. The syndrome is frequently associated with tumors, and its appearance often signals the presence of a concurrent or occult tumor. Anti-tumor therapy and immunotherapy remain the two major management approaches in treatment. Considering that early intervention has the potential to enhance neurological function and improve the prognosis in patients with Ri-PNS, it could be given particular attention in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.